Congenital Heart Disease Screening in Children
Introduction
Congenital heart disease (CHD) screening refers to the standardized medical evaluation conducted within the newborn period to detect cardiac structural abnormalities. As one of the most prevalent birth defects, CHD affects 0.8%-1% of live births and constitutes a leading cause of neonatal mortality and disability. Critical cardiac malformations often require surgical intervention within days to weeks after birth, where diagnostic delays may prove fatal. Asymptomatic mild cases risk progressing to heart failure or pulmonary hypertension if undetected. Implementing early screening protocols enables timely diagnosis, significantly improving clinical outcomes through prompt therapeutic management.
Why Choose China
Advanced Technology
China’s “Dual-Indicator Newborn CHD Screening Protocol” (cardiac auscultation + pulse oximetry) has screened 129,523 newborns, setting a global sample size record. This screening protocol combines cardiac auscultation and percutaneous pulse oximetry conducted 6-72 hours after birth, achieving 93.06% sensitivity and 97.98% specificity in detecting critical CHD. It demonstrates higher accuracy than Western single-indicator methods (75%-79% detection rate), effectively identifying life-threatening CHD variants with normal oxygen saturation. The non-invasive, low-cost screening system has been published in The Lancet (IF: 168.9) and 12 other top medical journals, receiving the EVE Global Innovation Award in Neonatal Health and Shanghai Municipal Science & Technology Progress First Prize. International experts from the UK, US, and Canada have endorsed this approach as the new gold standard.
Congenital Heart Disease Screening in Children
Introduction
Congenital heart disease (CHD) screening refers to the standardized medical evaluation conducted within the newborn period to detect cardiac structural abnormalities. As one of the most prevalent birth defects, CHD affects 0.8%-1% of live births and constitutes a leading cause of neonatal mortality and disability. Critical cardiac malformations often require surgical intervention within days to weeks after birth, where diagnostic delays may prove fatal. Asymptomatic mild cases risk progressing to heart failure or pulmonary hypertension if undetected. Implementing early screening protocols enables timely diagnosis, significantly improving clinical outcomes through prompt therapeutic management.
Why Choose China
Advanced Technology
China’s “Dual-Indicator Newborn CHD Screening Protocol” (cardiac auscultation + pulse oximetry) has screened 129,523 newborns, setting a global sample size record. This screening protocol combines cardiac auscultation and percutaneous pulse oximetry conducted 6-72 hours after birth, achieving 93.06% sensitivity and 97.98% specificity in detecting critical CHD. It demonstrates higher accuracy than Western single-indicator methods (75%-79% detection rate), effectively identifying life-threatening CHD variants with normal oxygen saturation. The non-invasive, low-cost screening system has been published in The Lancet (IF: 168.9) and 12 other top medical journals, receiving the EVE Global Innovation Award in Neonatal Health and Shanghai Municipal Science & Technology Progress First Prize. International experts from the UK, US, and Canada have endorsed this approach as the new gold standard.